Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Talbutal is a short to intermediate-acting barbiturate that acts as a nonselective central nervous system (CNS) depressant. It is capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma; at sufficiently high therapeutic doses it can induce anesthesia. Talbutal binds to a distinct site on the GABAA receptor associated with the chloride ion channel (Cl− ionopore), increasing the duration for which the channel remains open and thereby prolonging the inhibitory effect of GABA at postsynaptic thalamic neurons. It was primarily used as a sedative and hypnotic under the brand name Lotusate but has since been discontinued for these indications in many markets[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on talbutal.